William R Ewing

USPTO Granted Patents = 85 (Patent Applications = 9)

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 31 (Patent Applications = 25)

Average Co-Inventor Count = 5.4

ph-index = 11

Forward Citations = 374(Granted Patents)

Forward Citations (Not Self Cited) = 341(Oct 12, 2025)

Inventors with similar research interests:

Location History:

King of Prussia, PA (US) (1992 - 1997)
Downingtown, PA (US) (1998 - 2003)
Yardley, NJ (US) (2017)
Yadley, PA (US) (2019)
Yardley, PA (US) (2006 - 2024)
Princeton, NJ (US) (2024)

Company Filing History:

70 out of 3,681

Bristol-myers Squibb Compnay

patents

6 out of 111

Rhone-poulenc Rorer Pharmaceuticals Inc.

patents

3 out of 330

Aventis Pharma Deutschland, Gmbh

Aventis Pharmaceuticals Inc.

patents

6. 2 out of 1,186

The Scripps Research Institute

patents

7. 1 out of 2,595

University of Pennsylvania

patents

where one patent can have more than one assignee

Years Active: 1992-2025

Loading Chart...

85 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12428421 - Pyrimidinones as factor XIA inhibitors (2025-09-30),

2. 12077558 - Phosphorus (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophosphorus (V) compounds (2024-09-03),

3. 12065505 - Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof (2024-08-20),

4. 11613554 - Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds (2023-03-28),

5. 11192891 - Diazaspiro ROCK inhibitors (2021-12-07),

6. 11083704 - Method of administering nitroxyl donating compounds (2021-08-10),

7. 11053247 - Pyrimidinones as factor XIA inhibitors (2021-07-06),

8. 10752641 - Diamide macrocycles having factor XIa inhibiting activity (2020-08-25),

9. 10676477 - Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group (2020-06-09),

10. 10336754 - Pyrimidinones as factor XIa inhibitors (2019-07-02),

11. 10336730 - Substituted glycine derived FXIA inhibitors (2019-07-02),

12. 10287288 - Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties (2019-05-14),

13. 10273236 - Macrocyclic factor XIa inhibitors bearing heterocyclic groups (2019-04-30),

14. 10208068 - Macrocycles as factor XIa inhibitors (2019-02-19),

15. 10160750 - Diamide macrocycles as factor XIa inhibitors (2018-12-25),

Title: The Innovative Journey of William R Ewing

Introduction: William R Ewing, a distinguished inventor hailing from Yardley, PA, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: William R Ewing's latest patents showcase his commitment to innovation, with a focus on cutting-edge technologies in the realms of artificial intelligence and renewable energy.

Career Highlights: Throughout his illustrious career, William R Ewing has been at the forefront of technological advancements, revolutionizing industries with his inventive solutions. His work has not only garnered critical acclaim but has also significantly impacted the way we interact with technology on a daily basis.

Collaborations: William R Ewing's collaborative efforts with leading tech companies and research institutions have been instrumental in bringing his visionary ideas to life. By partnering with experts in various fields, he has been able to push the boundaries of innovation and create solutions that have a lasting impact.

Conclusion: In conclusion, William R Ewing's passion for innovation and his relentless pursuit of technological advancement have solidified his position as a trailblazer in the world of inventions. His contributions continue to inspire future generations of inventors to push the limits of what is possible in the ever-evolving landscape of technology.

This text is generated by artificial intelligence and may not be accurate.